Compare Abbott Laboratories (ABT) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Mondaycom Ltd — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Mondaycom Ltd trades at $81.5 (market cap $3.61B). The key difference: Abbott Laboratories is far larger — about 46.2× Mondaycom Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| ABT | MNDY | |
|---|---|---|
Market Cap | $166.94B | $3.61B |
Sector | Health | Technology |
52-Week High | $136.62 | $309.62 |
52-Week Low | $82.57 | $58.81 |
Enterprise Value | $193.69B | $2.57B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Monday.com (MNDY) trades at $82.50, up 3.42% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $1.15 vs. $0.96 expected) and impressive 89% gross margins. Recent news highlights institutional interest despite some insider selling, while technical indicators suggest the stock is approaching resistance at $84.
The outlook remains positive with a $116.75 consensus price target (41% upside potential), though risks include high valuation multiples (P/E 36, EV/EBITDA 111) and projected negative cash flow in 2026. Revenue growth stability at 9%+ net margins supports the bullish case, but investors should monitor competitive pressures in the SaaS sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
